person · Reporting owner
McCamish Mark Anthony
Disclosed activity across 4 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Rafael Holdings, Inc.RFL · Entity 6620 | Director | January 05, 2024 | January 08, 2024 |
| Vincerx Pharma, Inc.VINC · Entity 84409 | Director | December 23, 2020 | December 28, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Rafael Holdings, Inc.
Report date January 05, 2024 · Filed January 08, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Common Stock, par value $.01 per shareSEC Table I · non-derivative | Direct | 60,241 |
Reported balance
After 2024-01-05 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-01-05 · Grant · Acquired 27,655 · Balance 60,241 F1: Grant of Restricted Stock that vests in full immediately. F2: Represents the average closing price of the Issuer's Class B common stock during December 2023. F3: Consists of fully vested shares of Restricted Stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of Restricted Stock that vests in full immediately.
F2: Represents the average closing price of the Issuer's Class B common stock during December 2023.
F3: Consists of fully vested shares of Restricted Stock.
Vincerx Pharma, Inc.
Report date December 23, 2020 · Filed December 28, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.00 · Expires 2030-12-23 | Direct | 6,667 |
Reported balance
After 2020-12-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-12-23 · Grant · Acquired 6,667 · Balance 6,667 F1: The option vests in full on the earlier of December 23, 2021, the next annual meeting of stockholders or the consummation of a change of control, subject to the director's continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in full on the earlier of December 23, 2021, the next annual meeting of stockholders or the consummation of a change of control, subject to the director's continued service.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
AVADEL PHARMACEUTICALS PLC
Report date February 12, 2026 · Filed February 12, 2026
Section 16 reporting ended · disclosed 2026-02-12. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-02-12 transaction · row 1
1 source rowRow 1 · 2026-02-12 · Disposition to issuer · Disposed 22,000 · Balance 0 F1: Reflects the disposition of ordinary shares of Avadel Pharmaceuticals plc ("Issuer"), nominal value $0.01 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement, dated as of October 22, 2025, as amended by Amendment No. 1 to the Transaction Agreement dated November 18, 2025, (together the "Transaction Agreement") by and between Issuer and Alkermes plc ("Parent"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme") pursuant to which Parent acquired Issuer. F2: Pursuant to the Transaction Agreement, on February 12, 2026, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $21.00 in cash (the "Cash Consideration") and a non-transferable contingent value right entitling the holders to a potential additional cash payment of $1.50 per share, contingent upon achievement of certain milestones (each a "CVR"). F3: Includes Ordinary Shares previously subject to vesting restrictions or forfeiture back to Issuer (each, a "Restricted Stock Award"). Pursuant to the Transaction Agreement, at the Effective time, each Restricted Stock Award that was outstanding immediately prior to the Effective Time vested in full and was treated in the manner described in footnote 1. |
| Ordinary SharesSEC Table I · non-derivative | IndirectBy McCamish Charitable Remainder Trust | 0 |
Reported balance
After 2026-02-12 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-02-12 · Disposition to issuer · Disposed 67,025 · Balance 0 F1: Reflects the disposition of ordinary shares of Avadel Pharmaceuticals plc ("Issuer"), nominal value $0.01 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement, dated as of October 22, 2025, as amended by Amendment No. 1 to the Transaction Agreement dated November 18, 2025, (together the "Transaction Agreement") by and between Issuer and Alkermes plc ("Parent"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme") pursuant to which Parent acquired Issuer. F2: Pursuant to the Transaction Agreement, on February 12, 2026, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $21.00 in cash (the "Cash Consideration") and a non-transferable contingent value right entitling the holders to a potential additional cash payment of $1.50 per share, contingent upon achievement of certain milestones (each a "CVR"). F4: Shares held by McCamish Charitable Remainder Trust, of which the Reporting Person and his spouse are income beneficiaries. The Reporting Person disclaims beneficial ownership except to the extent of his and his spouse's pecuniary interest therein. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.92 · Expires 2029-12-05 | Direct | 0 |
Reported balance
After 2026-02-12 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-02-12 · Disposition to issuer · Disposed 60,000 · Balance 0 F5: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.48 · Expires 2030-08-07 | Direct | 0 |
Reported balance
After 2026-02-12 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-02-12 · Disposition to issuer · Disposed 42,000 · Balance 0 F5: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.30 · Expires 2030-09-13 | Direct | 0 |
Reported balance
After 2026-02-12 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-02-12 · Disposition to issuer · Disposed 50,000 · Balance 0 F5: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.07 · Expires 2031-08-03 | Direct | 0 |
Reported balance
After 2026-02-12 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-02-12 · Disposition to issuer · Disposed 42,000 · Balance 0 F5: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.79 · Expires 2032-08-03 | Direct | 0 |
Reported balance
After 2026-02-12 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-02-12 · Disposition to issuer · Disposed 42,000 · Balance 0 F5: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.10 · Expires 2033-08-01 | Direct | 0 |
Reported balance
After 2026-02-12 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-02-12 · Disposition to issuer · Disposed 33,000 · Balance 0 F5: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.32 · Expires 2034-07-30 | Direct | 0 |
Reported balance
After 2026-02-12 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-02-12 · Disposition to issuer · Disposed 11,000 · Balance 0 F5: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.83 · Expires 2035-07-29 | Direct | 0 |
Reported balance
After 2026-02-12 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-02-12 · Disposition to issuer · Disposed 11,000 · Balance 0 F5: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the disposition of ordinary shares of Avadel Pharmaceuticals plc ("Issuer"), nominal value $0.01 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement, dated as of October 22, 2025, as amended by Amendment No. 1 to the Transaction Agreement dated November 18, 2025, (together the "Transaction Agreement") by and between Issuer and Alkermes plc ("Parent"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme") pursuant to which Parent acquired Issuer.
F2: Pursuant to the Transaction Agreement, on February 12, 2026, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $21.00 in cash (the "Cash Consideration") and a non-transferable contingent value right entitling the holders to a potential additional cash payment of $1.50 per share, contingent upon achievement of certain milestones (each a "CVR").
F3: Includes Ordinary Shares previously subject to vesting restrictions or forfeiture back to Issuer (each, a "Restricted Stock Award"). Pursuant to the Transaction Agreement, at the Effective time, each Restricted Stock Award that was outstanding immediately prior to the Effective Time vested in full and was treated in the manner described in footnote 1.
F4: Shares held by McCamish Charitable Remainder Trust, of which the Reporting Person and his spouse are income beneficiaries. The Reporting Person disclaims beneficial ownership except to the extent of his and his spouse's pecuniary interest therein.
F5: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting).
Forty Seven, Inc.
Report date April 07, 2020 · Filed April 07, 2020
Section 16 reporting ended · disclosed 2020-04-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-04-07 transaction · row 1
1 source rowRow 1 · 2020-04-07 · Disposition to issuer · Disposed 4,595 · Balance 0 F1: Disposed of pursuant to an agreement and plan of merger by and between the Issuer, Gilead Sciences, Inc. ("Gilead") and Toro Merger Sub, Inc. ("Purchaser") (the "Merger") in exchange for $95.50 per share, net to the holder in cash, without interest and subject to any withholding of taxes, upon the terms and subject to the conditions described in the Offer to Purchase dated March 10, 2020 (together with any amendments or supplements thereto, the "Offer to Purchase") and in the accompanying Letter of Transmittal (together with any amendments or supplements thereto), which are annexed to and filed with the Schedule TO as Exhibits (a)(1)(A) and (a)(1)(B), respectively. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.88 · Expires 2027-06-07 | Direct | 0 |
Reported balance
After 2020-04-07 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-04-07 · Disposition to issuer · Disposed 314,395 · Balance 0 F2: This option, which provided for vesting over a four year period as follows: (i) 96,773 shares subject to the option vested on May 1, 2018, and (ii) the balance of the shares subject to the option vesting in a series of 36 successive equal monthly installments thereafter, subject to the Reporting Person's continuous service as of each such date, was accelerated and canceled in the Merger in exchange for a cash payment of $28,489,688.91, representing the difference between the market value of the common stock underlying the option on the effective date of the Merger ($95.50 per share) and the exercise price applicable to each share of common stock underlying the option, which difference is multiplied by the total number of shares of common stock subject to the option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.88 · Expires 2027-08-14 | Direct | 0 |
Reported balance
After 2020-04-07 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-04-07 · Disposition to issuer · Disposed 134,629 · Balance 0 F3: This option, which provided for vesting over a four-year period as follows: 1/48th of the shares subject to the option vest in a series of 48 successive equal monthly installments beginning August 15, 2017, subject to the Reporting Person's continuous service as of each such date, was accelerated and canceled in the Merger in exchange for a cash payment of $12,199,743.41, representing the difference between the market value of the common stock underlying the option on the effective date of the Merger ($95.50 per share) and the exercise price applicable to each share of common stock underlying the option, which difference is multiplied by the total number of shares of common stock subject to the option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.27 · Expires 2027-11-27 | Direct | 0 |
Reported balance
After 2020-04-07 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-04-07 · Disposition to issuer · Disposed 334,239 · Balance 0 F4: This option, which provided for vesting over a four-year period as follows: 1/48th of the shares subject to the option vest in a series of 48 successive equal monthly installments beginning November 8, 2017, subject to Reporting Person's continuous service as of each such date, was accelerated and canceled in the Merger in exchange for a cash payment of $30,158,384.97, representing the difference between the market value of the common stock underlying the option on the effective date of the Merger ($95.50 per share) and the exercise price applicable to each share of common stock underlying the option, which difference is multiplied by the total number of shares of common stock subject to the option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.76 · Expires 2028-04-26 | Direct | 0 |
Reported balance
After 2020-04-07 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-04-07 · Disposition to issuer · Disposed 184,516 · Balance 0 F5: This option, which provided for vesting over a four-year period as follows: 1/48th of the shares subject to the option vest in a series of 48 successive equal monthly installments beginning March 1, 2019, subject to Reporting Person's continuous service as of each such date, was accelerated and canceled in the Merger in exchange for a cash payment of $16,005,379.13, representing the difference between the market value of the common stock underlying the option on the effective date of the Merger ($95.50 per share) and the exercise price applicable to each share of common stock underlying the option, which difference is multiplied by the total number of shares of common stock subject to the option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.75 · Expires 2029-12-12 | Direct | 0 |
Reported balance
After 2020-04-07 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-04-07 · Disposition to issuer · Disposed 327,375 · Balance 0 F6: This option, which provided for vesting over a four-year period as follows: 1/48th of the shares subject to the option vest in a series of 48 successive equal monthly installments beginning December 13, 2019, subject to Reporting Person's continuous service as of each such date, was accelerated and canceled in the Merger in exchange for a cash payment of $19,560,656.25, representing the difference between the market value of the common stock underlying the option on the effective date of the Merger ($95.50 per share) and the exercise price applicable to each share of common stock underlying the option, which difference is multiplied by the total number of shares of common stock subject to the option. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to an agreement and plan of merger by and between the Issuer, Gilead Sciences, Inc. ("Gilead") and Toro Merger Sub, Inc. ("Purchaser") (the "Merger") in exchange for $95.50 per share, net to the holder in cash, without interest and subject to any withholding of taxes, upon the terms and subject to the conditions described in the Offer to Purchase dated March 10, 2020 (together with any amendments or supplements thereto, the "Offer to Purchase") and in the accompanying Letter of Transmittal (together with any amendments or supplements thereto), which are annexed to and filed with the Schedule TO as Exhibits (a)(1)(A) and (a)(1)(B), respectively.
F2: This option, which provided for vesting over a four year period as follows: (i) 96,773 shares subject to the option vested on May 1, 2018, and (ii) the balance of the shares subject to the option vesting in a series of 36 successive equal monthly installments thereafter, subject to the Reporting Person's continuous service as of each such date, was accelerated and canceled in the Merger in exchange for a cash payment of $28,489,688.91, representing the difference between the market value of the common stock underlying the option on the effective date of the Merger ($95.50 per share) and the exercise price applicable to each share of common stock underlying the option, which difference is multiplied by the total number of shares of common stock subject to the option.
F3: This option, which provided for vesting over a four-year period as follows: 1/48th of the shares subject to the option vest in a series of 48 successive equal monthly installments beginning August 15, 2017, subject to the Reporting Person's continuous service as of each such date, was accelerated and canceled in the Merger in exchange for a cash payment of $12,199,743.41, representing the difference between the market value of the common stock underlying the option on the effective date of the Merger ($95.50 per share) and the exercise price applicable to each share of common stock underlying the option, which difference is multiplied by the total number of shares of common stock subject to the option.
F4: This option, which provided for vesting over a four-year period as follows: 1/48th of the shares subject to the option vest in a series of 48 successive equal monthly installments beginning November 8, 2017, subject to Reporting Person's continuous service as of each such date, was accelerated and canceled in the Merger in exchange for a cash payment of $30,158,384.97, representing the difference between the market value of the common stock underlying the option on the effective date of the Merger ($95.50 per share) and the exercise price applicable to each share of common stock underlying the option, which difference is multiplied by the total number of shares of common stock subject to the option.
F5: This option, which provided for vesting over a four-year period as follows: 1/48th of the shares subject to the option vest in a series of 48 successive equal monthly installments beginning March 1, 2019, subject to Reporting Person's continuous service as of each such date, was accelerated and canceled in the Merger in exchange for a cash payment of $16,005,379.13, representing the difference between the market value of the common stock underlying the option on the effective date of the Merger ($95.50 per share) and the exercise price applicable to each share of common stock underlying the option, which difference is multiplied by the total number of shares of common stock subject to the option.
F6: This option, which provided for vesting over a four-year period as follows: 1/48th of the shares subject to the option vest in a series of 48 successive equal monthly installments beginning December 13, 2019, subject to Reporting Person's continuous service as of each such date, was accelerated and canceled in the Merger in exchange for a cash payment of $19,560,656.25, representing the difference between the market value of the common stock underlying the option on the effective date of the Merger ($95.50 per share) and the exercise price applicable to each share of common stock underlying the option, which difference is multiplied by the total number of shares of common stock subject to the option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 12, 2026 Filed Feb 12, 2026 17:33 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | Disposition to issuerStock Option (Right to Buy) · Derivative | 11,000 | Not disclosed Strike: $10.83 | Not disclosed |
DisclosureSEC source: 0001104659-26-014444 · tm266121-5_4seq1.xml · derivative · entry 10 McCamish Mark Anthony · CIK 0001390798 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 11,000 shares Expires 2035-07-29 F5 · kind: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). F5 · price: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). F5 · derivative.exercise_date: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). Read SEC document |
| February 12, 2026 Filed Feb 12, 2026 17:33 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | Disposition to issuerStock Option (Right to Buy) · Derivative | 11,000 | Not disclosed Strike: $16.32 | Not disclosed |
DisclosureSEC source: 0001104659-26-014444 · tm266121-5_4seq1.xml · derivative · entry 9 McCamish Mark Anthony · CIK 0001390798 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 11,000 shares Expires 2034-07-30 F5 · kind: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). F5 · price: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). F5 · derivative.exercise_date: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). Read SEC document |
| February 12, 2026 Filed Feb 12, 2026 17:33 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | Disposition to issuerStock Option (Right to Buy) · Derivative | 33,000 | Not disclosed Strike: $14.10 | Not disclosed |
DisclosureSEC source: 0001104659-26-014444 · tm266121-5_4seq1.xml · derivative · entry 8 McCamish Mark Anthony · CIK 0001390798 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 33,000 shares Expires 2033-08-01 F5 · kind: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). F5 · price: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). F5 · derivative.exercise_date: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). Read SEC document |
| February 12, 2026 Filed Feb 12, 2026 17:33 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | Disposition to issuerStock Option (Right to Buy) · Derivative | 42,000 | Not disclosed Strike: $4.79 | Not disclosed |
DisclosureSEC source: 0001104659-26-014444 · tm266121-5_4seq1.xml · derivative · entry 7 McCamish Mark Anthony · CIK 0001390798 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 42,000 shares Expires 2032-08-03 F5 · kind: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). F5 · price: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). F5 · derivative.exercise_date: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). Read SEC document |
| February 12, 2026 Filed Feb 12, 2026 17:33 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | Disposition to issuerStock Option (Right to Buy) · Derivative | 42,000 | Not disclosed Strike: $8.07 | Not disclosed |
DisclosureSEC source: 0001104659-26-014444 · tm266121-5_4seq1.xml · derivative · entry 6 McCamish Mark Anthony · CIK 0001390798 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 42,000 shares Expires 2031-08-03 F5 · kind: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). F5 · price: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). F5 · derivative.exercise_date: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). Read SEC document |
| February 12, 2026 Filed Feb 12, 2026 17:33 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | Disposition to issuerStock Option (Right to Buy) · Derivative | 50,000 | Not disclosed Strike: $5.30 | Not disclosed |
DisclosureSEC source: 0001104659-26-014444 · tm266121-5_4seq1.xml · derivative · entry 5 McCamish Mark Anthony · CIK 0001390798 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 50,000 shares Expires 2030-09-13 F5 · kind: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). F5 · price: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). F5 · derivative.exercise_date: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). Read SEC document |
| February 12, 2026 Filed Feb 12, 2026 17:33 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | Disposition to issuerStock Option (Right to Buy) · Derivative | 42,000 | Not disclosed Strike: $8.48 | Not disclosed |
DisclosureSEC source: 0001104659-26-014444 · tm266121-5_4seq1.xml · derivative · entry 4 McCamish Mark Anthony · CIK 0001390798 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 42,000 shares Expires 2030-08-07 F5 · kind: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). F5 · price: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). F5 · derivative.exercise_date: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). Read SEC document |
| February 12, 2026 Filed Feb 12, 2026 17:33 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | Disposition to issuerStock Option (Right to Buy) · Derivative | 60,000 | Not disclosed Strike: $5.92 | Not disclosed |
DisclosureSEC source: 0001104659-26-014444 · tm266121-5_4seq1.xml · derivative · entry 3 McCamish Mark Anthony · CIK 0001390798 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 60,000 shares Expires 2029-12-05 F5 · kind: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). F5 · price: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). F5 · derivative.exercise_date: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). Read SEC document |
| February 12, 2026 Filed Feb 12, 2026 17:33 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | Disposition to issuerOrdinary Shares | 67,025 | $21.00 | $1,407,525.00 |
DisclosureSEC source: 0001104659-26-014444 · tm266121-5_4seq1.xml · nonDerivative · entry 2 McCamish Mark Anthony · CIK 0001390798 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By McCamish Charitable Remainder Trust Disclosed balance after: 0 F1 · kind: Reflects the disposition of ordinary shares of Avadel Pharmaceuticals plc ("Issuer"), nominal value $0.01 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement, dated as of October 22, 2025, as amended by Amendment No. 1 to the Transaction Agreement dated November 18, 2025, (together the "Transaction Agreement") by and between Issuer and Alkermes plc ("Parent"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme") pursuant to which Parent acquired Issuer. F2 · kind: Pursuant to the Transaction Agreement, on February 12, 2026, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $21.00 in cash (the "Cash Consideration") and a non-transferable contingent value right entitling the holders to a potential additional cash payment of $1.50 per share, contingent upon achievement of certain milestones (each a "CVR"). F1 · price: Reflects the disposition of ordinary shares of Avadel Pharmaceuticals plc ("Issuer"), nominal value $0.01 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement, dated as of October 22, 2025, as amended by Amendment No. 1 to the Transaction Agreement dated November 18, 2025, (together the "Transaction Agreement") by and between Issuer and Alkermes plc ("Parent"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme") pursuant to which Parent acquired Issuer. F2 · price: Pursuant to the Transaction Agreement, on February 12, 2026, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $21.00 in cash (the "Cash Consideration") and a non-transferable contingent value right entitling the holders to a potential additional cash payment of $1.50 per share, contingent upon achievement of certain milestones (each a "CVR"). F4 · ownership.nature: Shares held by McCamish Charitable Remainder Trust, of which the Reporting Person and his spouse are income beneficiaries. The Reporting Person disclaims beneficial ownership except to the extent of his and his spouse's pecuniary interest therein. Read SEC document |
| February 12, 2026 Filed Feb 12, 2026 17:33 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | Disposition to issuerOrdinary Shares | 22,000 | $21.00 | $462,000.00 |
DisclosureSEC source: 0001104659-26-014444 · tm266121-5_4seq1.xml · nonDerivative · entry 1 McCamish Mark Anthony · CIK 0001390798 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: Reflects the disposition of ordinary shares of Avadel Pharmaceuticals plc ("Issuer"), nominal value $0.01 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement, dated as of October 22, 2025, as amended by Amendment No. 1 to the Transaction Agreement dated November 18, 2025, (together the "Transaction Agreement") by and between Issuer and Alkermes plc ("Parent"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme") pursuant to which Parent acquired Issuer. F2 · kind: Pursuant to the Transaction Agreement, on February 12, 2026, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $21.00 in cash (the "Cash Consideration") and a non-transferable contingent value right entitling the holders to a potential additional cash payment of $1.50 per share, contingent upon achievement of certain milestones (each a "CVR"). F3 · shares: Includes Ordinary Shares previously subject to vesting restrictions or forfeiture back to Issuer (each, a "Restricted Stock Award"). Pursuant to the Transaction Agreement, at the Effective time, each Restricted Stock Award that was outstanding immediately prior to the Effective Time vested in full and was treated in the manner described in footnote 1. F1 · price: Reflects the disposition of ordinary shares of Avadel Pharmaceuticals plc ("Issuer"), nominal value $0.01 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement, dated as of October 22, 2025, as amended by Amendment No. 1 to the Transaction Agreement dated November 18, 2025, (together the "Transaction Agreement") by and between Issuer and Alkermes plc ("Parent"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme") pursuant to which Parent acquired Issuer. F2 · price: Pursuant to the Transaction Agreement, on February 12, 2026, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $21.00 in cash (the "Cash Consideration") and a non-transferable contingent value right entitling the holders to a potential additional cash payment of $1.50 per share, contingent upon achievement of certain milestones (each a "CVR"). Read SEC document |
| February 04, 2026 Filed Feb 6, 2026 16:10 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | GiftOrdinary Shares | 67,025 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-011511 · tm265492-1_4seq1.xml · nonDerivative · entry 2 McCamish Mark Anthony · CIK 0001390798 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By McCamish Charitable Remainder Trust Disclosed balance after: 67,025 F1 · kind: On February 4, 2026, the Reporting Person transferred 67,025 shares from Matthew 5 LLC to the McCamish Charitable Remainder Trust. F3 · ownership.nature: Shares held by McCamish Charitable Remainder Trust, of which the Reporting Person and his spouse are income beneficiaries. The Reporting Person disclaims beneficial ownership except to the extent of his and his spouse's pecuniary interest therein. Read SEC document |
| February 04, 2026 Filed Feb 6, 2026 16:10 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | GiftOrdinary Shares | 67,025 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-011511 · tm265492-1_4seq1.xml · nonDerivative · entry 1 McCamish Mark Anthony · CIK 0001390798 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Matthew 5 LLC Disclosed balance after: 0 F1 · kind: On February 4, 2026, the Reporting Person transferred 67,025 shares from Matthew 5 LLC to the McCamish Charitable Remainder Trust. F2 · ownership.nature: Shares held by Matthew 5 LLC. The Mark & Barbara McCamish Family Trust is the sole owner of Matthew 5 LLC, and the Reporting Person serves as its manager. Read SEC document |
| July 29, 2025 Filed Jul 31, 2025 16:10 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | GrantStock Option (Right to Buy) · Derivative | 11,000 | $0.00 Strike: $10.83 | $0.00 |
DisclosureSEC source: 0001104659-25-072695 · tm2522138-6_4seq1.xml · derivative · entry 3 McCamish Mark Anthony · CIK 0001390798 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,000 Underlying: Ordinary Shares · 11,000 shares Expires 2035-07-29 F3 · derivative.exercise_date: The options shall vest in full on the earlier to occur of (a) July 29, 2026 or (b) the date of the next annual general meeting of shareholders following the date of grant, subject to the Reporting Person's continued service at such time. Read SEC document |
| July 29, 2025 Filed Jul 31, 2025 16:10 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | GrantOrdinary Shares | 11,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-072695 · tm2522138-6_4seq1.xml · nonDerivative · entry 1 McCamish Mark Anthony · CIK 0001390798 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,000 F1 · shares: Represents a restricted share award. The shares shall vest in full on the earlier to occur of (a) July 29, 2026 or (b) the date of the next annual general meeting of shareholders following the date of grant, subject to the Reporting Person's continued service at such time. Read SEC document |
| July 30, 2024 Filed Aug 1, 2024 16:32 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | GrantStock Option (Right to Buy) · Derivative | 11,000 | $0.00 Strike: $16.32 | $0.00 |
DisclosureSEC source: 0001104659-24-084930 · tm2420652-2_4seq1.xml · derivative · entry 3 McCamish Mark Anthony · CIK 0001390798 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,000 Underlying: Ordinary Shares · 11,000 shares Expires 2034-07-30 F3 · derivative.exercise_date: The options shall vest in full on the earlier to occur of (a) July 30, 2025 or (b) the date of the next annual general meeting of shareholders following the date of grant, subject to the Reporting Person's continued service at such time. Read SEC document |
| July 30, 2024 Filed Aug 1, 2024 16:32 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | GrantOrdinary Shares | 11,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-084930 · tm2420652-2_4seq1.xml · nonDerivative · entry 1 McCamish Mark Anthony · CIK 0001390798 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,000 F1 · shares: Represents restricted share units ("RSUs"). Each RSU represents the contingent right to receive one Ordinary Share upon vesting and settlement. The RSUs shall vest in full on the earlier to occur of (a) July 30, 2025 or (b) the date of the next annual general meeting of shareholders following the date of grant, subject to the Reporting Person's continued service at such time. Read SEC document |
| January 05, 2024 Filed Jan 8, 2024 10:14 UTC | Rafael Holdings, Inc. RFL · Entity 6620 | GrantClass B Common Stock, par value $.01 per share | 27,655 | $1.81 | $50,055.55 |
DisclosureSEC source: 0001209191-24-001097 · doc4.xml · nonDerivative · entry 1 McCamish Mark Anthony · CIK 0001390798 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,241 F1 · shares: Grant of Restricted Stock that vests in full immediately. F2 · price: Represents the average closing price of the Issuer's Class B common stock during December 2023. F3 · balance_after: Consists of fully vested shares of Restricted Stock. Read SEC document |
| December 28, 2023 Filed Dec 29, 2023 16:15 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | SaleADSs | 75,000 | $14.53 | $1,089,750.00 |
DisclosureSEC source: 0001104659-23-130483 · tm2333942-1_4seq1.xml · nonDerivative · entry 1 McCamish Mark Anthony · CIK 0001390798 · Director 10b5-1 filing: Plan reported Ownership: Indirect · By Matthew 5 LLC Disclosed balance after: 67,025 F1 · security: The Issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the Issuer; ADSs may be represented by American Depositary Receipts. F2 · kind: These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on September 25, 2023. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.50 to $14.69, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F4 · ownership.nature: Shares held by Matthew 5 LLC. The Mark & Barbara McCamish Family Trust is the sole owner of Matthew 5 LLC, and the Reporting Person serves as its manager. Read SEC document |
| August 11, 2023 Filed Aug 15, 2023 16:13 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | SaleADSs | 28,975 | $14.93 | $432,614.14 |
DisclosureSEC source: 0001104659-23-091957 · tm2323851-1_4seq1.xml · nonDerivative · entry 1 McCamish Mark Anthony · CIK 0001390798 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Matthew 5 LLC Disclosed balance after: 142,025 F1 · security: The Issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the Issuer; ADSs may be represented by American Depositary Receipts. F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $14.75 to $15.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F3 · ownership.nature: Shares held by Matthew 5 LLC. The Mark & Barbara McCamish Family Trust is the sole owner of Matthew 5 LLC, and the Reporting Person serves as its manager. Read SEC document |
| August 01, 2023 Filed Aug 3, 2023 16:17 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | GrantStock Option (Right to Buy) · Derivative | 33,000 | $0.00 Strike: $14.10 | $0.00 |
DisclosureSEC source: 0001104659-23-087289 · tm2322778-3_4seq1.xml · derivative · entry 1 McCamish Mark Anthony · CIK 0001390798 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,000 Underlying: ADSs · 33,000 shares Expires 2033-08-01 F1 · derivative.exercise_date: Options shall vest in full on the earlier to occur of (a) August 1, 2024 or (b) the date of the next annual general meeting of shareholders following the date of grant, subject to the Reporting Person's continued service on the Board of Directors at such time. F2 · derivative.underlying: The Issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts. Read SEC document |
| January 05, 2023 Filed Jan 5, 2023 14:31 UTC | Rafael Holdings, Inc. RFL · Entity 6620 | GrantClass B Common Stock, par value $.01 per share | 27,174 | $1.84 | $50,000.16 |
DisclosureSEC source: 0001209191-23-001686 · doc4.xml · nonDerivative · entry 1 McCamish Mark Anthony · CIK 0001390798 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,586 F1 · shares: Grant of Restricted Stock that vests in full immediately. F2 · price: Represents the average closing price of the Issuer's Class B common stock during December 2022. F3 · balance_after: Consists of fully vested shares of Restricted Stock. Read SEC document |
| August 03, 2022 Filed Aug 5, 2022 17:13 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | GrantStock Option (Right to Buy) · Derivative | 42,000 | $0.00 Strike: $4.79 | $0.00 |
DisclosureSEC source: 0001104659-22-086772 · tm2222707-3_4seq1.xml · derivative · entry 1 McCamish Mark Anthony · CIK 0001390798 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,000 Underlying: ADSs · 42,000 shares Expires 2032-08-03 F1 · derivative.exercise_date: Options shall vest in full on the earlier to occur of (a) August 3, 2023 or (b) the date of the next annual general meeting of shareholders following the date of grant, subject to the Reporting Person's continued service on the Board of Directors at such time. F2 · derivative.underlying: The Issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts. Read SEC document |
| January 05, 2022 Filed Jan 5, 2022 12:34 UTC | Rafael Holdings, Inc. RFL · Entity 6620 | GrantClass B Common Stock, par value $.01 per share | 5,412 | $5.39 | $29,170.68 |
DisclosureSEC source: 0001209191-22-001452 · doc4.xml · nonDerivative · entry 1 McCamish Mark Anthony · CIK 0001390798 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,412 F1 · shares: Grant of Restricted Stock that vests in full immediately. F2 · price: Represents the average closing price of the Issuer's Class B common stock during December 2021. F3 · balance_after: Consists of fully vested shares of Restricted Stock. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 19:28 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | GrantStock Option (Right to Buy) · Derivative | 42,000 | $0.00 Strike: $8.07 | $0.00 |
DisclosureSEC source: 0001179110-21-007965 · edgar.xml · derivative · entry 1 McCamish Mark Anthony · CIK 0001390798 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,000 Underlying: ADSs · 42,000 shares Expires 2031-08-03 F1 · derivative.exercise_date: Options shall vest in full on the earlier to occur of (a) August 3, 2022 or (b) the date of the next annual general meeting of shareholders following the date of grant, subject to the Reporting Person's continued service on the Board of Directors at such time. F2 · derivative.underlying: The Issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts. Read SEC document |
| December 23, 2020 Filed Dec 28, 2020 21:26 UTC | Vincerx Pharma, Inc. VINC · Entity 84409 | GrantStock Option (right to buy) · Derivative | 6,667 | $0.00 Strike: $19.00 | $0.00 |
DisclosureSEC source: 0000899243-20-035393 · doc4.xml · derivative · entry 1 McCamish Mark Anthony · CIK 0001390798 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,667 Underlying: Common Stock · 6,667 shares Expires 2030-12-23 F1 · derivative.exercise_date: The option vests in full on the earlier of December 23, 2021, the next annual meeting of stockholders or the consummation of a change of control, subject to the director's continued service. Read SEC document |
| September 17, 2020 Filed Sep 18, 2020 16:20 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | PurchaseADSs | 52,398 | $5.83 | $305,249.79 |
DisclosureSEC source: 0001179110-20-009879 · edgar.xml · nonDerivative · entry 2 McCamish Mark Anthony · CIK 0001390798 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Matthew 5 LLC Disclosed balance after: 171,000 F1 · security: The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts. F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.68 to $5.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F3 · ownership.nature: Shares held by Matthew 5 LLC. The Mark & Barbara McCamish Family Trust is the sole owner of Matthew 5 LLC, and the Reporting Person serves as its manager. Read SEC document |
| September 16, 2020 Filed Sep 18, 2020 16:20 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | PurchaseADSs | 118,602 | $5.73 | $679,968.99 |
DisclosureSEC source: 0001179110-20-009879 · edgar.xml · nonDerivative · entry 1 McCamish Mark Anthony · CIK 0001390798 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Matthew 5 LLC Disclosed balance after: 118,602 F1 · security: The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts. F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.25 to $5.895, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F3 · ownership.nature: Shares held by Matthew 5 LLC. The Mark & Barbara McCamish Family Trust is the sole owner of Matthew 5 LLC, and the Reporting Person serves as its manager. Read SEC document |
| September 13, 2020 Filed Sep 14, 2020 07:17 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $5.30 | $0.00 |
DisclosureSEC source: 0001179110-20-009709 · edgar.xml · derivative · entry 1 McCamish Mark Anthony · CIK 0001390798 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: ADSs · 50,000 shares Expires 2030-09-13 F1 · derivative.exercise_date: The stock options shall vest and become exercisable in the following manner: 33% on September 13, 2021; 33% on September 13, 2022; and the remaining 34% on September 13, 2023. F2 · derivative.underlying: The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts. Read SEC document |
| August 07, 2020 Filed Aug 11, 2020 16:58 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | GrantStock Option (Right to Buy) · Derivative | 42,000 | $0.00 Strike: $8.48 | $0.00 |
DisclosureSEC source: 0001179110-20-008893 · edgar.xml · derivative · entry 1 McCamish Mark Anthony · CIK 0001390798 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,000 Underlying: ADSs · 42,000 shares Expires 2020-08-07 F1 · derivative.exercise_date: Options become exercisable as to 14,000 ADSs on each of the first three anniversaries after the 08/07/2020 grant date. F2 · derivative.underlying: The Issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by AmericanDepositary Receipts. Read SEC document |
| April 07, 2020 Filed Apr 7, 2020 12:11 UTC | Forty Seven, Inc. FTSV · Entity 16035 | Disposition to issuerStock Option (right to buy) · Derivative | 327,375 | Not disclosed Strike: $35.75 | Not disclosed |
DisclosureSEC source: 0001209191-20-023711 · doc4.xml · derivative · entry 6 McCamish Mark Anthony · CIK 0001390798 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 327,375 shares Expires 2029-12-12 F6 · price: This option, which provided for vesting over a four-year period as follows: 1/48th of the shares subject to the option vest in a series of 48 successive equal monthly installments beginning December 13, 2019, subject to Reporting Person's continuous service as of each such date, was accelerated and canceled in the Merger in exchange for a cash payment of $19,560,656.25, representing the difference between the market value of the common stock underlying the option on the effective date of the Merger ($95.50 per share) and the exercise price applicable to each share of common stock underlying the option, which difference is multiplied by the total number of shares of common stock subject to the option. F6 · derivative.exercise_date: This option, which provided for vesting over a four-year period as follows: 1/48th of the shares subject to the option vest in a series of 48 successive equal monthly installments beginning December 13, 2019, subject to Reporting Person's continuous service as of each such date, was accelerated and canceled in the Merger in exchange for a cash payment of $19,560,656.25, representing the difference between the market value of the common stock underlying the option on the effective date of the Merger ($95.50 per share) and the exercise price applicable to each share of common stock underlying the option, which difference is multiplied by the total number of shares of common stock subject to the option. Read SEC document |
| April 07, 2020 Filed Apr 7, 2020 12:11 UTC | Forty Seven, Inc. FTSV · Entity 16035 | Disposition to issuerStock Option (right to buy) · Derivative | 184,516 | Not disclosed Strike: $8.76 | Not disclosed |
DisclosureSEC source: 0001209191-20-023711 · doc4.xml · derivative · entry 5 McCamish Mark Anthony · CIK 0001390798 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 184,516 shares Expires 2028-04-26 F5 · price: This option, which provided for vesting over a four-year period as follows: 1/48th of the shares subject to the option vest in a series of 48 successive equal monthly installments beginning March 1, 2019, subject to Reporting Person's continuous service as of each such date, was accelerated and canceled in the Merger in exchange for a cash payment of $16,005,379.13, representing the difference between the market value of the common stock underlying the option on the effective date of the Merger ($95.50 per share) and the exercise price applicable to each share of common stock underlying the option, which difference is multiplied by the total number of shares of common stock subject to the option. F5 · derivative.exercise_date: This option, which provided for vesting over a four-year period as follows: 1/48th of the shares subject to the option vest in a series of 48 successive equal monthly installments beginning March 1, 2019, subject to Reporting Person's continuous service as of each such date, was accelerated and canceled in the Merger in exchange for a cash payment of $16,005,379.13, representing the difference between the market value of the common stock underlying the option on the effective date of the Merger ($95.50 per share) and the exercise price applicable to each share of common stock underlying the option, which difference is multiplied by the total number of shares of common stock subject to the option. Read SEC document |
| April 07, 2020 Filed Apr 7, 2020 12:11 UTC | Forty Seven, Inc. FTSV · Entity 16035 | Disposition to issuerStock Option (right to buy) · Derivative | 334,239 | Not disclosed Strike: $5.27 | Not disclosed |
DisclosureSEC source: 0001209191-20-023711 · doc4.xml · derivative · entry 4 McCamish Mark Anthony · CIK 0001390798 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 334,239 shares Expires 2027-11-27 F4 · price: This option, which provided for vesting over a four-year period as follows: 1/48th of the shares subject to the option vest in a series of 48 successive equal monthly installments beginning November 8, 2017, subject to Reporting Person's continuous service as of each such date, was accelerated and canceled in the Merger in exchange for a cash payment of $30,158,384.97, representing the difference between the market value of the common stock underlying the option on the effective date of the Merger ($95.50 per share) and the exercise price applicable to each share of common stock underlying the option, which difference is multiplied by the total number of shares of common stock subject to the option. F4 · derivative.exercise_date: This option, which provided for vesting over a four-year period as follows: 1/48th of the shares subject to the option vest in a series of 48 successive equal monthly installments beginning November 8, 2017, subject to Reporting Person's continuous service as of each such date, was accelerated and canceled in the Merger in exchange for a cash payment of $30,158,384.97, representing the difference between the market value of the common stock underlying the option on the effective date of the Merger ($95.50 per share) and the exercise price applicable to each share of common stock underlying the option, which difference is multiplied by the total number of shares of common stock subject to the option. Read SEC document |
| April 07, 2020 Filed Apr 7, 2020 12:11 UTC | Forty Seven, Inc. FTSV · Entity 16035 | Disposition to issuerStock Option (right to buy) · Derivative | 134,629 | Not disclosed Strike: $4.88 | Not disclosed |
DisclosureSEC source: 0001209191-20-023711 · doc4.xml · derivative · entry 3 McCamish Mark Anthony · CIK 0001390798 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 134,629 shares Expires 2027-08-14 F3 · price: This option, which provided for vesting over a four-year period as follows: 1/48th of the shares subject to the option vest in a series of 48 successive equal monthly installments beginning August 15, 2017, subject to the Reporting Person's continuous service as of each such date, was accelerated and canceled in the Merger in exchange for a cash payment of $12,199,743.41, representing the difference between the market value of the common stock underlying the option on the effective date of the Merger ($95.50 per share) and the exercise price applicable to each share of common stock underlying the option, which difference is multiplied by the total number of shares of common stock subject to the option. F3 · derivative.exercise_date: This option, which provided for vesting over a four-year period as follows: 1/48th of the shares subject to the option vest in a series of 48 successive equal monthly installments beginning August 15, 2017, subject to the Reporting Person's continuous service as of each such date, was accelerated and canceled in the Merger in exchange for a cash payment of $12,199,743.41, representing the difference between the market value of the common stock underlying the option on the effective date of the Merger ($95.50 per share) and the exercise price applicable to each share of common stock underlying the option, which difference is multiplied by the total number of shares of common stock subject to the option. Read SEC document |
| April 07, 2020 Filed Apr 7, 2020 12:11 UTC | Forty Seven, Inc. FTSV · Entity 16035 | Disposition to issuerStock Option (right to buy) · Derivative | 314,395 | Not disclosed Strike: $4.88 | Not disclosed |
DisclosureSEC source: 0001209191-20-023711 · doc4.xml · derivative · entry 2 McCamish Mark Anthony · CIK 0001390798 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 314,395 shares Expires 2027-06-07 F2 · price: This option, which provided for vesting over a four year period as follows: (i) 96,773 shares subject to the option vested on May 1, 2018, and (ii) the balance of the shares subject to the option vesting in a series of 36 successive equal monthly installments thereafter, subject to the Reporting Person's continuous service as of each such date, was accelerated and canceled in the Merger in exchange for a cash payment of $28,489,688.91, representing the difference between the market value of the common stock underlying the option on the effective date of the Merger ($95.50 per share) and the exercise price applicable to each share of common stock underlying the option, which difference is multiplied by the total number of shares of common stock subject to the option. F2 · derivative.exercise_date: This option, which provided for vesting over a four year period as follows: (i) 96,773 shares subject to the option vested on May 1, 2018, and (ii) the balance of the shares subject to the option vesting in a series of 36 successive equal monthly installments thereafter, subject to the Reporting Person's continuous service as of each such date, was accelerated and canceled in the Merger in exchange for a cash payment of $28,489,688.91, representing the difference between the market value of the common stock underlying the option on the effective date of the Merger ($95.50 per share) and the exercise price applicable to each share of common stock underlying the option, which difference is multiplied by the total number of shares of common stock subject to the option. Read SEC document |
| April 07, 2020 Filed Apr 7, 2020 12:11 UTC | Forty Seven, Inc. FTSV · Entity 16035 | Disposition to issuerCommon Stock | 4,595 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-023711 · doc4.xml · nonDerivative · entry 1 McCamish Mark Anthony · CIK 0001390798 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Disposed of pursuant to an agreement and plan of merger by and between the Issuer, Gilead Sciences, Inc. ("Gilead") and Toro Merger Sub, Inc. ("Purchaser") (the "Merger") in exchange for $95.50 per share, net to the holder in cash, without interest and subject to any withholding of taxes, upon the terms and subject to the conditions described in the Offer to Purchase dated March 10, 2020 (together with any amendments or supplements thereto, the "Offer to Purchase") and in the accompanying Letter of Transmittal (together with any amendments or supplements thereto), which are annexed to and filed with the Schedule TO as Exhibits (a)(1)(A) and (a)(1)(B), respectively. F1 · price: Disposed of pursuant to an agreement and plan of merger by and between the Issuer, Gilead Sciences, Inc. ("Gilead") and Toro Merger Sub, Inc. ("Purchaser") (the "Merger") in exchange for $95.50 per share, net to the holder in cash, without interest and subject to any withholding of taxes, upon the terms and subject to the conditions described in the Offer to Purchase dated March 10, 2020 (together with any amendments or supplements thereto, the "Offer to Purchase") and in the accompanying Letter of Transmittal (together with any amendments or supplements thereto), which are annexed to and filed with the Schedule TO as Exhibits (a)(1)(A) and (a)(1)(B), respectively. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 17:50 UTC | Forty Seven, Inc. FTSV · Entity 16035 | Exercise / conversionStock Option (right to buy) · Derivative | 27 | $0.00 Strike: $4.88 | $0.00 |
DisclosureSEC source: 0001209191-20-023385 · doc4.xml · derivative · entry 6 McCamish Mark Anthony · CIK 0001390798 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,629 Underlying: Common Stock · 27 shares Expires 2027-08-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to the option vest in a series of 48 successive equal monthly installments beginning August 15, 2017, subject to the Reporting Person's continuous service as of each such date. The shares subject to this option may be exercised prior to vesting, subject to the Issuer's right to repurchase. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 17:50 UTC | Forty Seven, Inc. FTSV · Entity 16035 | Exercise / conversionStock Option (right to buy) · Derivative | 30,210 | $0.00 Strike: $4.88 | $0.00 |
DisclosureSEC source: 0001209191-20-023385 · doc4.xml · derivative · entry 5 McCamish Mark Anthony · CIK 0001390798 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 314,395 Underlying: Common Stock · 30,210 shares Expires 2027-06-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 96,773 shares subject to the option vested on May 1, 2018 and the balance of the shares subject to the option vest in a series of 36 successive equal monthly installments beginning June 1, 2018, subject to the Reporting Person's continuous service as of each such date. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 17:50 UTC | Forty Seven, Inc. FTSV · Entity 16035 | SaleCommon Stock | 30,237 | $95.42 | $2,885,235.71 |
DisclosureSEC source: 0001209191-20-023385 · doc4.xml · nonDerivative · entry 4 McCamish Mark Anthony · CIK 0001390798 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,595 Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 17:50 UTC | Forty Seven, Inc. FTSV · Entity 16035 | SaleCommon Stock | 2,340 | $95.41 | $223,268.29 |
DisclosureSEC source: 0001209191-20-023385 · doc4.xml · nonDerivative · entry 3 McCamish Mark Anthony · CIK 0001390798 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,832 Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 17:50 UTC | Forty Seven, Inc. FTSV · Entity 16035 | Exercise / conversionCommon Stock | 30,237 | $4.88 | $147,632.15 |
DisclosureSEC source: 0001209191-20-023385 · doc4.xml · nonDerivative · entry 2 McCamish Mark Anthony · CIK 0001390798 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,172 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 6,935 shares acquired under the Forty Seven, Inc. 2018 Employee Stock Purchase Plan. Read SEC document |
| March 16, 2020 Filed Apr 3, 2020 17:50 UTC | Forty Seven, Inc. FTSV · Entity 16035 | GiftCommon Stock | 60,719 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-023385 · doc4.xml · nonDerivative · entry 1 McCamish Mark Anthony · CIK 0001390798 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| December 13, 2019 Filed Dec 17, 2019 19:23 UTC | Forty Seven, Inc. FTSV · Entity 16035 | GrantStock Option (right to buy) · Derivative | 327,375 | $0.00 Strike: $35.75 | $0.00 |
DisclosureSEC source: 0001209191-19-061039 · doc4.xml · derivative · entry 1 McCamish Mark Anthony · CIK 0001390798 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 327,375 Underlying: Common Stock · 327,375 shares Expires 2029-12-12 F1 · derivative.exercise_date: The shares subject to the option vest in a series of 48 successive equal monthly installments beginning with the vesting commencement date, subject to Reporting Person's continuous service as of each such date. Read SEC document |
| December 05, 2019 Filed Dec 9, 2019 21:24 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | GrantStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $5.92 | $0.00 |
DisclosureSEC source: 0001179110-19-012567 · edgar.xml · derivative · entry 1 McCamish Mark Anthony · CIK 0001390798 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: ADSs · 60,000 shares Expires 2019-12-05 F1 · derivative.exercise_date: The stock options shall vest and become exercisable in the following manner: 33% on December 5, 2020; 33% on December 5, 2021; and the remaining 34% on December 5, 2022. F2 · derivative.underlying: The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts. Read SEC document |
| June 25, 2019 Filed Jun 27, 2019 18:22 UTC | Forty Seven, Inc. FTSV · Entity 16035 | Exercise / conversionStock Option (right to buy) · Derivative | 8,199 | $0.00 Strike: $4.88 | $0.00 |
DisclosureSEC source: 0001209191-19-039347 · doc4.xml · derivative · entry 3 McCamish Mark Anthony · CIK 0001390798 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 344,605 Underlying: Common Stock · 8,199 shares Expires 2027-06-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/4th of the shares subject to the option vested on May 1, 2018 and the balance of the shares subject to the option vest in a series of 36 successive equal monthly installments thereafter, subject to the Reporting Person's continuous service as of each such date. Read SEC document |
| June 25, 2019 Filed Jun 27, 2019 18:22 UTC | Forty Seven, Inc. FTSV · Entity 16035 | SaleCommon Stock | 8,199 | $11.02 | $90,390.70 |
DisclosureSEC source: 0001209191-19-039347 · doc4.xml · nonDerivative · entry 2 McCamish Mark Anthony · CIK 0001390798 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,719 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $11.00 to $11.20, inclusive. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 25, 2019 Filed Jun 27, 2019 18:22 UTC | Forty Seven, Inc. FTSV · Entity 16035 | Exercise / conversionCommon Stock | 8,199 | $4.88 | $40,031.62 |
DisclosureSEC source: 0001209191-19-039347 · doc4.xml · nonDerivative · entry 1 McCamish Mark Anthony · CIK 0001390798 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,918 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 20, 2019 Filed Jun 24, 2019 17:39 UTC | Forty Seven, Inc. FTSV · Entity 16035 | Exercise / conversionStock Option (right to buy) · Derivative | 8,301 | $0.00 Strike: $4.88 | $0.00 |
DisclosureSEC source: 0001209191-19-038824 · doc4.xml · derivative · entry 3 McCamish Mark Anthony · CIK 0001390798 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 352,804 Underlying: Common Stock · 8,301 shares Expires 2027-06-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/4th of the shares subject to the option vested on May 1, 2018 and the balance of the shares subject to the option vest in a series of 36 successive equal monthly installments thereafter, subject to the Reporting Person's continuous service as of each such date. Read SEC document |
| June 20, 2019 Filed Jun 24, 2019 17:39 UTC | Forty Seven, Inc. FTSV · Entity 16035 | SaleCommon Stock | 8,301 | $11.04 | $91,626.44 |
DisclosureSEC source: 0001209191-19-038824 · doc4.xml · nonDerivative · entry 2 McCamish Mark Anthony · CIK 0001390798 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,719 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $11.00 to $11.20, inclusive. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 20, 2019 Filed Jun 24, 2019 17:39 UTC | Forty Seven, Inc. FTSV · Entity 16035 | Exercise / conversionCommon Stock | 8,301 | $4.88 | $40,529.63 |
DisclosureSEC source: 0001209191-19-038824 · doc4.xml · nonDerivative · entry 1 McCamish Mark Anthony · CIK 0001390798 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,020 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 20, 2019 Filed May 22, 2019 20:15 UTC | Forty Seven, Inc. FTSV · Entity 16035 | Exercise / conversionStock Option (right to buy) · Derivative | 1,291 | $0.00 Strike: $4.88 | $0.00 |
DisclosureSEC source: 0001209191-19-032180 · doc4.xml · derivative · entry 6 McCamish Mark Anthony · CIK 0001390798 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 361,105 Underlying: Common Stock · 1,291 shares Expires 2027-06-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 1/4th of the shares subject to the option vested on May 1, 2018 and the balance of the shares subject to the option vest in a series of 36 successive equal monthly installments thereafter, subject to the Reporting Person's continuous service as of each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.